Serafin Morales Murillo

Oliveira, M; Villagrasa, P; Ciruelos, E; Gavila, J; Cortegoso, A; Henao, F; Vega, E; Bofill, JS; Quiroga, V; Garcia-Estevez, L; Morales, S; Tolosa, P; Celiz, P; Farre, XG; Saura, C

Solti-1507 A phase ib study of ipatasertib and anti-her2 therapy in her2-positive advanced breast cancer with pik3ca mutation (ipather)

CANCER RESEARCH 81 -. 01/02/2021.

Prat, A; Gavila, J; Pernas, S; Cruz, J; Saura, C; Nogales, E; Bermejo, M; Bofill, JS; Quiroga, V; Garcia-Estevez, L; Morales, S; Servitja, S; del Toro, R; Galvan, P; Chic, N; Martinez, D; Braso-Maristany, F; Canes, J; Pare, L; Ferrero-Cafiero, JM; Villagrasa, P

Solti-1804 HER2-PREDICT: A biomarker research study of DS8201-A-U301-U302 and-U303 trials

CANCER RESEARCH 81 -. 01/02/2021.

Saura, C; Ciruelos, E; Vidal, M; Garrigos, L; Margeli, M; Morales, S; Gonzalez-Farre, X; Bofill, JS; Blancas, I; Gasent, JM; Lopez-Miranda, E; Godoy, A; Iglesias, M; Sanchez-Rovira, P; Hernao, F; Gallegos, I; Pulido, C; Alves, S; Branco, D; Passos-Coelho, J; Escriva-de-Romani, S; Ferrero-Cafiero, JM; Villagrasa, P; Prat, A

Solti-1718 NEREA trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-Enriched (HER2-E) advanced breast cancer (BC)

CANCER RESEARCH 81 -. 01/02/2021.

Schmid P; Sablin MP; Bergh J; Im SA; Lu YS; Martínez N; Neven P; Lee KS; Morales S; Pérez-Fidalgo JA; Adamson D; Gonçalves A; Prat A; Jerusalem G; Schlieker L; Espadero RM; Bogenrieder T; Huang DC; Crown J; Cortés J

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.

BREAST CANCER RESEARCH 23 8-8. 15/01/2021.

[doi:10.1186/s13058-020-01382-8]

Jimenez, MM; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Ciruelos, EM; Munoz, M; Bermejo, B; Margeli, M; Csoszi, T; Anton, A; Turner, N; Casas, MI; Morales, S; Alba, E; Calvo, L; De la Haba, J; Ramos, M; Corsaro, M; Kahan, Z; Gil-Gil, M

Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

ANNALS OF ONCOLOGY 32 457-458. 01/01/2021.

[doi:10.1016/j.annonc.2021.08.512]

Ciruelos E; Villagrasa P; Pascual T; Oliveira M; Pernas S; Paré L; Escrivá-de-Romaní S; Manso L; Adamo B; Martínez E; Cortés J; Vazquez S; Perelló A; Garau I; Melé M; Martínez N; Montaño A; Bermejo B; Morales S; Echarri MJ; Vega E; González-Farré B; Martínez D; Galván P; Canes J; Nuciforo P; Gonzalez X; Prat A

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial.

CLINICAL CANCER RESEARCH 26 5820-5829. 15/11/2020.

[doi:10.1158/1078-0432.CCR-20-0844]

Quintela-Fandino M; Holgado E; Manso L; Morales S; Bermejo B; Colomer R; Apala JV; Blanco R; Muñoz M; Caleiras E; Iranzo V; Martinez M; Dominguez O; Hornedo J; Gonzalez-Cortijo L; Cortes J; Gasol Cudos A; Malon D; Lopez-Alonso A; Moreno-Ortíz MC; Mouron S; Mañes S

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.

BREAST CANCER RESEARCH 22 124-124. 11/11/2020.

[doi:10.1186/s13058-020-01362-y]

Griguolo, G; Serna, G; Pascual, T; Fasani, R; Chic, N; Pare, L; Pernas, S; Munoz, M; Oliveira, M; Vidal, M; Cussac, AL; Cortes, J; Galvan, P; Bermejo, B; Martinez, N; Lopez, R; Morales, S; Villagrasa, P; Prat, A; Nuciforo, P

Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)

ANNALS OF ONCOLOGY 31 19-19. 01/05/2020.

[doi:10.1016/j.annonc.2020.03.144]

Morales, S; Cudos, AG; Galindo, AR; Velasco, A; Morales, CC; Guzman, DRS; Olive, JM

Loss of HER2 after neoadjuvant treatment of HER2+early breast cancer

ANNALS OF ONCOLOGY 31 51-51. 01/05/2020.

[doi:10.1016/j.annonc.2020.03.042]

Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Ciruelos, E; Munoz, M; Bermejo, B; Margeli, M; Turner, N; Casas, M; Anton, A; Csoszi, T; Corsaro, M; Murillo, L; Morales, S; Alba, E; Bartlett, CH; Koehler, M; Guerrero, A; Kahan, Z; Gil-Gil, M

Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

CANCER RESEARCH 80 -. 01/02/2020.

[doi:10.1158/1538-7445.SABCS19-GS2-07]

Braso-Maristany, F; Griguolo, G; Pascual, T; Pare, L; Nuciforo, P; Llombart-Cussac, A; Bermejo, B; Oliveira, M; Morales, S; Martinez, N; Vidal, M; Adamo, B; Martinez, O; Pernas, S; Lopez, R; Muñoz M; Chic, N; Galvan, P; Garau, I; Manso, L; Alarcon, J; Martinez, E; Gregorio, S; Gomis, RR; Villagrasa, P; Cortes, J; Ciruelos, E; Prat, A

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

Nature Communications 11 385-385. 20/01/2020.

[doi:10.1038/s41467-019-14111-3]

Quintela-Fandino, M; Morales, S; Cortes-Salgado, A; Manso, L; Apala, JV; Munoz, M; Cudos, AG; Fortuny, JS; Gion, M; Lopez-Alonso, A; Cortes, J; Guerra, J; Malon, D; Caleiras, E; Mulero, F; Mouron, S

Randomized Phase O/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

CLINICAL CANCER RESEARCH 26 35-45. 01/01/2020.

[doi:10.1158/1078-0432.CCR-19-2023]